Why is Travere Therapeutics stock sliding today?

Travere Therapeutics stock is sliding 4.3% in pre-open trading today after the company’s third-quarter 2026 results, reported after Monday’s market close, delivered a significant earnings miss despite a standout revenue beat. The company posted an adjusted loss of $0.55 per share against the analyst consensus estimate for a profit of $0.02, while revenue reached $224.56 million, topping the $195.68 million consensus by nearly 15%. The earnings shortfall was primarily driven by a $113.1 million in-process research and development expense related to the company’s exclusive licensing and collaboration agreement with Everest Medicines for civorebrutinib.

On the analyst front, Leerink Partners cut its price target for Travere Therapeutics to $67 from $78 today, compounding the post-earnings pressure in pre-market. Adding to investor caution, Q3 FILSPARI sales benefited by approximately $8 million from elevated specialty-pharmacy inventory, which is expected to reverse in Q4 as distributors return to normal stock levels — a forward headwind that tempers the otherwise impressive top-line momentum. CEO Eric Dube also sold 243,735 shares of company stock in mid-October at an average price of $53.82, totaling over $13 million, while the company is navigating a leadership transition with a new CEO set to take over in December.

On the broader market front, the pre-market backdrop on today’s Election Day is mixed rather than uniformly negative. Dow futures were down 0.7% while Nasdaq-100 futures were up 0.4%, meaning the weakness in TVTX is clearly company-specific rather than a reflection of broad market selling. FILSPARI’s U.S. net product sales of $200.2 million in Q3 represented 120% year-over-year growth, with 1,932 new patient start forms received during the quarter, underscoring that the commercial trajectory remains strong even as the earnings miss dominates today’s price action.

Taken together, the combination of a deeply missed earnings estimate driven by a large one-time pipeline investment charge, a fresh analyst price target reduction, a flagged Q4 inventory headwind, and ongoing leadership uncertainty has overwhelmed the positive revenue story, pushing shares to trade at $47.16 — well below the prior close of $49.26 and meaningfully beneath the stock’s 52-week high of $68.73, though still comfortably above its 52-week low of $22.59.